Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine
NCT ID: NCT01488110
Last Updated: 2013-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
40 participants
INTERVENTIONAL
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of a New Treatment for Migraine Attacks
NCT01880671
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
NCT02991430
Chordate System S020 Acute Migraine Clinical Investigation
NCT02185703
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
NCT00358839
Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
NCT02227758
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Migraine medical device
Treatment with an active nasal probe
In-house prototype invented by Jan-Erik Juto
30 minutes treatment with an active nasal probe.
Inactive migraine medical device
Treatment with an inactive nasal probe.
In-house prototype invented by Jan-Erik Juto
30 minutes treatment with an inactive nasal probe.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
In-house prototype invented by Jan-Erik Juto
30 minutes treatment with an active nasal probe.
In-house prototype invented by Jan-Erik Juto
30 minutes treatment with an inactive nasal probe.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
* Subjects with a minimum of 1 migraine attack per month
* Attack duration of 4 to 72 hours
* Normal attack intensity of at least 4 on a 0-10 VAS-scale
Exclusion Criteria
* Cardiovascular diseases
* Vascular damages on neck vessels
* Diseases other than migraine of the CNS
* Severe disease of vital body organs
* Severe psychiatric disorders
* More than 6 migraine attacks per month
20 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jan-Erik Juto
Adjunct professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juto
Role: PRINCIPAL_INVESTIGATOR
Karolinska University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital, Huddinge
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Migraine2011/1609-31/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.